Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Singletine (DC407) in Healthy Adults
NCT06160401Phase 1Completed
- Sponsor
- Guangzhou JOYO Pharma
- Start
- Aug 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of singletine in type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) (4 arms), sponsored by Guangzhou JOYO Pharma. Primary endpoint: Treatment-Emergent Adverse Events. Started Aug 2020; status: completed.
02
Drugs
singletine
03
Conditions
type 2 diabetes mellitus (T2DM)non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT06160401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06160401.